Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET | Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering-logo (1).png
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET | Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering-logo (1).png
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:05 ET | Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering-logo (1).png
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023 09:00 ET | Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immuneering-logo (1).png
Immuneering Announces Participation in March Investor Conferences
February 28, 2023 08:00 ET | Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering-logo (1).png
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023 08:00 ET | Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...